Literature DB >> 27264017

Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer.

Elliot A Asare1, Douglas B Evans1, Beth A Erickson2, Murad Aburajab3, Parag Tolat4, Susan Tsai1.   

Abstract

Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291-295.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  cost-effectiveness; healthcare value; neoadjuvant therapy; pancreatic cancer

Mesh：

Substances：

Year:  2016        PMID： 27264017     DOI： 10.1002/jso.24316

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  7 in total

Review 1.  Recent Advances in Pancreatic Cancer Surgery.

Authors:  Laura Maggino; Charles M Vollmer
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

2.  Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis.

Authors:  Alison Bradley; Robert Van Der Meer
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

3.  Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis.

Authors:  Alison Bradley; Robert Van Der Meer
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

4.  Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA.

Authors:  ChongFeng Gao; Luke Wisniewski; Ying Liu; Ben Staal; Ian Beddows; Dennis Plenker; Mohammed Aldakkak; Johnathan Hall; Daniel Barnett; Mirna Kheir Gouda; Peter Allen; Richard Drake; Amer Zureikat; Ying Huang; Douglas Evans; Aatur Singhi; Randall E Brand; David A Tuveson; Susan Tsai; Brian B Haab
Journal:  Clin Cancer Res       Date:  2020-10-22       Impact factor: 13.801

Review 5.  A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology.

Authors:  Robert E Van Sciver; Michael P Lee; Caroline Dasom Lee; Alex C Lafever; Elizaveta Svyatova; Kevin Kanda; Amber L Colliver; Lauren L Siewertsz van Reesema; Angela M Tang-Tan; Vasilena Zheleva; Monicah N Bwayi; Minglei Bian; Rebecca L Schmidt; Lynn M Matrisian; Gloria M Petersen; Amy H Tang
Journal:  Cancers (Basel)       Date:  2018-05-14       Impact factor: 6.639

6.  A prognostic Bayesian network that makes personalized predictions of poor prognostic outcome post resection of pancreatic ductal adenocarcinoma.

Authors:  Alison Bradley; Robert Van der Meer; Colin J McKay
Journal:  PLoS One       Date:  2019-09-09       Impact factor: 3.240

Review 7.  Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature.

Authors:  Ester Oneda; Alberto Zaniboni
Journal:  J Clin Med       Date:  2019-11-08       Impact factor: 4.241
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.